Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHATIMA
2023-509321-50-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab and pertuzumab in breast cancer (3 arms), sponsored by Roche. Primary endpoints: Average healthcare professional time per patient per visit (cycles 2–7) and Average patient time per visit (cycles 2–7). Planned start Jan 2024; status: authorised.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-509321-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509321-50-00.